DSpace@İnönü

Comparison of first-line eradication therapy protocols for Helicobacter pylori in regions with high clarithromycin resistance

Basit öğe kaydını göster

dc.contributor.author Bozkurt, Hilmi
dc.contributor.author Sert, Ozlem Zeliha
dc.contributor.author Kaplan, Esin
dc.contributor.author Aray, Emre
dc.contributor.author Olmez, Tolga
dc.contributor.author Uzun, Orhan
dc.contributor.author Koksal, Rabia
dc.contributor.author Polat, Erdal
dc.contributor.author Duman, Mustafa
dc.date.accessioned 2022-03-01T15:06:16Z
dc.date.available 2022-03-01T15:06:16Z
dc.date.issued 2019
dc.identifier.citation Bozkurt, H., Zeliha Sert, O., Kaplan, E., Aray, E., Olmez, T., Uzun, O., Koksal, R., Polat, E., & Duman, M. (2021). Comparison of first-line eradication therapy protocols for Helicobacter pylori in regions with high clarithromycin resistance . Annals of Medical Research en_US
dc.identifier.uri http://hdl.handle.net/11616/54153
dc.description.abstract Aim: First-line eradication therapy protocols for Helicobacter pylori infection and their success rates still prove to be matter of interest for researchers. The aim of this study was to examine retrospectively eradication therapy protocols used in patients infected with H. pylori in our region with high resistance to clarithromycin, compare success rates and determine the factors affecting success rates. Material and Methods: Eradication therapies for dyspeptic patients who were found to be Helicobacter pylori positive as revealed by upper gastrointestinal endoscopy and biopsy results and success rates attained in the microscopic examination of stool in the 4th week after the therapy were analyzed. Group 1 (legacy triple therapy): clarithromycin 500 mg film-coated tablet 2x1, lansoprazole 30 mg capsule 2x1, amoxicillin 1000 mg tablet 2x1, 14-day therapy period; Group 2 (bismuth-free quadruple therapy): clarithromycin 500 mg film tablet 2x1, rabeprazole 20 mg tablet 2*1, amoxicillin 1000 mg tablet 2x1, metronidazole 500mg 2x1 tablet, 14-day therapy period; Group 3 (bismuthal quadruple therapy): bismuth subsalicylate 262 mg tablet 2x2, metronidazole 500 mg tablet 3x1, tetracycline 500 mg capsule 3x1, pantoprazole 40mg tablet 2x1, 10-day therapy period.Results: Data of 168 patients were analyzed. The patients were divided into Group 1 (classical therapy) with 80 patients, Group 2 (bismuth-free quadruple therapy) with 46 patients and Group 3 (bismuthal quadruple therapy) with 42 patients. Eradication success rates were as follows: Group 1 (80%), Group 2 (80.4%) and Group 3 (83.3%).Conclusion: Antibiotic resistance is the sole reason for the low success rate in eradication therapy for Helicobacter pylori. In regions with high clarithromycin resistance bismuth-free quadruple therapy can be employed as an alternative. In regions with metronidazole resistance in addition to clarithromycin resistance bismuthal therapy protocols can be employed. Keywords: Helicobacter pylori; eradication therapy; clarithromycin resistance. en_US
dc.language.iso eng en_US
dc.rights info:eu-repo/semantics/openAccess en_US
dc.title Comparison of first-line eradication therapy protocols for Helicobacter pylori in regions with high clarithromycin resistance en_US
dc.type article en_US
dc.relation.journal Annals of Medical Research en_US
dc.contributor.department İnönü Üniversitesi en_US


Bu öğenin dosyaları:

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster